Lipids are chemical substances that are insoluble in water such as cholesterol and triglycerides. Hyperlipidemia is a medical condition marked by elevation of lipid level in the blood. This rise in lipid levels leads to increase in fatty deposits in arteries, which cause blockages in the arteries of the patient. The blockages can in turn lead to rise in risk related to heart attacks. Therefore, hyperlipidemia is a major medical condition that requires treatment. The drugs that are used to treat hyperlipidemia are called as antihyperlipidemic drugs. Some of the drugs available in the market include bile acid, sequestrants, cholesterol absorption inhibitors, and others.
The global market for Antihyperlipidemic Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Antihyperlipidemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Antihyperlipidemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Antihyperlipidemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Antihyperlipidemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Antihyperlipidemic Drug players cover Sanofi, Boehringer Ingelheim, Merck KGaA, Johnson and Johnson and Bayer AG, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This latest report provides a deep insight into the global Antihyperlipidemic Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Antihyperlipidemic Drug market, with both quantitative and qualitative data, to help readers understand how the Antihyperlipidemic Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
The study segments the Antihyperlipidemic Drug market and forecasts the market size by Type (Statins, PCSK9 Inhibitors and Bile Acid Chelators), by Application (Hospital Pharmacy, Online Pharmacy, Clinics and Others), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Bile Acid Chelators
Cholesterol Absorption Inhibitors
Segmentation by application
Segmentation by region
Middle East & Africa
Major companies covered
Johnson and Johnson
Takeda Pharmaceutical Co
Novartis International AG
Bristol Myers Squibb
Chapter 1: Scope of Antihyperlipidemic Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Antihyperlipidemic Drug market size and CAGR, Antihyperlipidemic Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Antihyperlipidemic Drug revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Antihyperlipidemic Drug revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Antihyperlipidemic Drug market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi, Boehringer Ingelheim, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Takeda Pharmaceutical Co, AstraZeneca and Daiichi Sankyo, etc.
Chapter 14: Research Findings and Conclusion